SJS Investment Consulting’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.9K Hold
541
– – ﹤0.01% 1296
2026
Q2
$9.36K Buy
541
+508
+1,539% +$6.96K ﹤0.01% 1107
2026
Q1
$411 Buy
33
+16
+94% +$215 ﹤0.01% 1803
2025
Q4
$215 Hold
17
– – ﹤0.01% 1785
2025
Q3
$171 Buy
+17
New +$153 ﹤0.01% 1499
2025
Q2
– Sell
-266
Closed -$2.23K – 1556
2025
Q1
$2.23K Buy
266
+258
+3,225% +$2.15K ﹤0.01% 679
2024
Q4
$64 Buy
+8
New +$67 ﹤0.01% 1547
2022
Q4
– Sell
-4
Closed – – 1602
2022
Q3
$0 Buy
+4
New +$11 ﹤0.01% 1023
2022
Q1
$0 Buy
+1
New +$4 ﹤0.01% 693

Other funds holding AMRX

SJS Investment Consulting's AMRX Position: Q3 2026 in Review

SJS Investment Consulting held its Amneal Pharmaceuticals (AMRX) position steady in Q3 2026 at 541 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

SJS Investment Consulting first reported a position in AMRX in Q1 2022 and has held it in 9 quarters since. 332 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • SJS Investment Consulting held 541 shares of Amneal Pharmaceuticals worth $10.9K as of Q3 2026.
  • SJS Investment Consulting left its Amneal Pharmaceuticals share count unchanged in Q3 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #1296 holding.
  • SJS Investment Consulting first reported a position in Amneal Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
  • 332 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.